Disrupting KRAS–AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer
Medicine
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.